Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Pavlo Kot
Pavlo Kot

Capital raise boosts Spyre Therapeutics funding to exceed 2 billion dollars

Capital raise boosts Spyre Therapeutics funding to exceed 2 billion dollars
Spyre raises 350 million dollars

Spyre Therapeutics has announced a new financing round of 350 million dollars to support the advancement of its SPY072 program into late stage development for hidradenitis suppurativa.

The additional funding brings the companys total capital raised to over 2 billion dollars since inception, with a current pro forma cash position of approximately 1.5 billion dollars.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Why do crypto companies want their own banks?
  • By Anastasiia Chabaniuk
  • 1 hour ago
Why do crypto companies want their own banks?
Editors' Picks
Between record and bubble: How Anthropic is approaching its IPO
  • By Mikhail Vnuchkov
  • 5 hours ago
Between record and bubble: How Anthropic is approaching its IPO
Editors' Picks
From Bitcoin to AI: How crypto companies are reinventing their businesses
  • By Olena Litvinenko
  • Yesterday
From Bitcoin to AI: How crypto companies are reinventing their businesses
Editors' Picks
All Editors' Top Picks

Latest Spyre News

Spyre Therapeutics investigates SPY003 as innovative monotherapy and combination approach
  • By Mykhailo Ihnatenko
  • 1 hour ago
Spyre Therapeutics investigates SPY003 as innovative monotherapy and combination approach
Companies
#Spyre
Spyre Therapeutics presents new clinical and preclinical data for SPY001 002 003 at UEGW2026
  • By Mikhail Vnuchkov
  • 18.10.2026
Spyre Therapeutics presents new clinical and preclinical data for SPY001 002 003 at UEGW2026
Companies
#Spyre
SPY003 demonstrates positive Phase 2 SKYLINE results in ulcerative colitis: Can SYRE break above $89.93?
  • By Viktoras Karapetjanc
  • 08.09.2026
SPY003 demonstrates positive Phase 2 SKYLINE results in ulcerative colitis: Can SYRE break above $89.93?
Companies
#Spyre
All Spyre News
  • Anastasiia Chabaniuk
  • 1 hour ago
Why do crypto companies want their own banks?
  • Mikhail Vnuchkov
  • 5 hours ago
Between record and bubble: How Anthropic is approaching its IPO
  • Olena Litvinenko
  • Yesterday
From Bitcoin to AI: How crypto companies are reinventing their businesses
  • Eugene Komchuk
  • Yesterday
Trezor security chief: It's easier to trick users than hack a crypto wallet
  • Dmytro Kharkov
  • Yesterday
How Ozempic and weight-loss drugs are quietly deflating beer volumes
  • Igor Krasulya
  • 11 min ago
Shay Huang: Trader discusses going from $3,000 loss to $1.6 million profit
  • Mikhail Vnuchkov
  • 13 min ago
Fears about bitcoin crashing to tens of thousands now seem ironic, Jameson Lopp notes
  • Mykhailo Ihnatenko
  • 13 min ago
CLO equity CEFs are ripe for acquisition and liquidation, Michael Kao notes
  • Mykhailo Ihnatenko
  • 26 min ago
Alexander Stahel: Shell company borrows $63 billion to buy Broadcom and Google-designed chips
  • Yaroslav Dmytrenko
  • 26 min ago
Layah Heilpern: KCEX offers 0 percent maker fees on futures and up to 470 USDT bonus for new users
Top News
  • Andrey Mastykin
  • 38 min ago
Oil prices fall as Tehran talks offer hope despite Saudi refinery attack
Oil prices fall as Tehran talks offer hope despite Saudi refinery attack
  • Hanna Syniavska
  • 2 hours ago
U.S. stock futures climb as tech shares and lower oil prices support markets
U.S. stock futures climb as tech shares and lower oil prices support markets
  • Igor Krasulya
  • 4 hours ago
Nvidia backs Meta AI ambitions with $3 billion investment
Nvidia backs Meta AI ambitions with $3 billion investment
  • Ezequiel Gomes
  • 4 hours ago
Crypto industry spends $176 million on U.S. congressional elections
Crypto industry spends $176 million on U.S. congressional elections
  • Ivan Andriyenko
  • 5 hours ago
Gold struggles to hold $4,000 amid U.S. inflation concerns
Gold struggles to hold $4,000 amid U.S. inflation concerns
Live News
  • Parshwa Turakhiya
  • Now
BlackRock teams up with SBI and Startale to advance tokenized finance in Japan
  • Anton Kharitonov
  • Now
EUR/USD remains vulnerable near October lows ahead of central bank decisions
  • Eugene Komchuk
  • Now
Galaxy recommends accumulating Bitcoin ahead of the next rally
  • Hanna Syniavska
  • Now
Revolut launches UK personal loans as it expands beyond everyday banking
  • Anton Kharitonov
  • Now
EUR/USD remains under pressure as eurozone growth weakens ahead of ECB decision
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers